Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson maintains a Speculative Buy rating on Genelux (NASDAQ:GNLX) but lowers the price target from $30 to $25.
May 31, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Benchmark analyst Bruce Jackson maintains a Speculative Buy rating on Genelux but lowers the price target from $30 to $25.
The lowered price target from $30 to $25 suggests a less optimistic outlook for Genelux, which could negatively impact short-term investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100